Akebia Therapeutics Inc

Akebia Therapeutics’ kidney‑disease biotech journey: stock struggles, promising HIF‑based drug Vafseo, and a critical path to profitability.

Akebia Therapeutics, a Cambridge‑based biotech, focuses on HIF‑based kidney disease drugs, blending research breakthroughs with investor‑friendly insights.

Akebia Therapeutics Inc is set to release its quarterly earnings on May 8, 2025, with analysts predicting a loss per share of $0.038 and revenue of $44.5 million, marking a potential turning point for the biotech company.